Search

Displaying results 3891 - 3900 of 8412 in total
  1. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.

  2. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

  3. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by mod...

  4. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor...

  5. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Currently dehydroascorbic acid is an experimental drug with no known approved indications. … This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid.

  6. Drug

    Hetacillin

    go.drugbank.com/drugs/DB00739
    ApprovedVet approvedWithdrawn

    The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins.

  7. Drug

    Clocortolone

    go.drugbank.com/drugs/DB00838
    Approved

    Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.

  8. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.

  9. Drug

    Reversin 121

    go.drugbank.com/drugs/DB14072
    Experimental

    Reversin 121 is a hydrophobic peptide chemosensitizer that can reverse P-glycoprotein-mediated multidrug resistance.

    Categories: P-glycoprotein inhibitors
  10. Drug

    AKN-028

    go.drugbank.com/drugs/DB12746
    Investigational

    AKN-028 has been used in trials studying the treatment of Acute Myeloid Leukemia.